Novo Nordisk shares were 9.5% higher after the pharmaceutical giant said an experimental weight-loss shot showed patients ...

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

A/S, a global healthcare giant specializing in diabetes care and obesity treatment, continues to dominate the GLP-1 drug market alongside competitor Eli Lilly (NYSE:LLY). With a market capitalization ...

Breakthrough in diabetes treatment! The US FDA approves Ozempic for reducing kidney disease risk in diabetic patients. Learn ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

This repeated cross-sectional study including 69.2 million obesity management drug dispensed prescriptions revealed an increase from 0.76 million in July 2017 to 1.5 million in February 2024, with an ...

Childhood obesity continues to be a growing problem in out country. So, should the government regulate food advertising like it did with cigarettes?

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a ...

(Reuters) -The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, ...

The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...

Patients taking Novo Nordisk’s Wegovy plus Veru’s enobosarm saw 71% lower lean mass loss than those who were taking Wegovy ...